Stephen Gardner to Antiviral Agents
This is a "connection" page, showing publications Stephen Gardner has written about Antiviral Agents.
Connection Strength
1.093
-
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects. Liver Int. 2014 Jul; 34(6):e89-95.
Score: 0.386
-
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol. 2008 May; 48(5):728-35.
Score: 0.261
-
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002 Jul; 36(1):186-94.
Score: 0.176
-
Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteers. Clin Ther. 2013 Jan; 35(1):68-76.
Score: 0.091
-
Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J. 2004 May; 23(5):441-5.
Score: 0.050
-
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004 Jan; 126(1):81-90.
Score: 0.049
-
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003 Dec; 125(6):1714-22.
Score: 0.049
-
Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol. 2011 Dec; 55(6):1195-200.
Score: 0.020
-
Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002 May 30; 346(22):1706-13.
Score: 0.011